DSO Acquisition Offers: What Dentists Actually Get Paid in 2026
DSOs pay 5x to 8x EBITDA for single-location general dental practices and 8x to 11x EBITDA for multi-location groups with $1M+ EBITDA in 2026, with specialty practices (orthodontics, oral surgery, endodontics) commanding 10x to 14x.
But the headline multiple is not what you take home. A typical DSO deal is 60-80% cash at close, 15-40% rollover equity, and the rest in earnouts tied to performance over 1-3 years.
The real number depends on what survives that structure.
This guide breaks down what DSOs actually pay in 2026, how the deal is structured, what the headline multiple hides, and how to read an offer.
For the underlying valuation math, see our dental practice valuation guide. To compare DSO offers against selling to an associate, see associate vs. DSO. Pennsylvania sellers should also review our Pennsylvania dental practice sale guide for state-specific licensing, Medicaid re-enrollment, and bulk sales requirements.
- What DSOs Actually Pay for Dental Practices in 2026
- The Single Biggest Driver: Scale
- How Normalized EBITDA Works (And Why It Matters)
- The DSO Deal Structure: What the Headline Hides
- What You Give Up: The Non-Financial Terms
- Who's Buying: The 2026 DSO Landscape
- How to Read a DSO Offer
- DSO Acquisition Offers FAQ
What DSOs Actually Pay for Dental Practices in 2026
DSOs value practices on normalized EBITDA, not collections or SDE.
The multiple scales sharply with size because larger practices carry less owner-dependence risk and fit platform roll-up math.
Single-location general dentistry (under $1M EBITDA): 5x to 7x EBITDA. Priced as small DSO tuck-ins. A practice at $400K EBITDA typically sells for $2.0M to $2.8M.
Regional add-ons ($1M-$3M EBITDA): 7x to 9x EBITDA. The sweet spot for DSO add-on activity. A 3-location group at $2.4M EBITDA can clear $16.8M to $21.6M enterprise value.
Emerging platforms ($3M-$5M EBITDA): 9x to 11x EBITDA. Practices large enough to anchor or seed a platform.
Platform-grade ($5M+ EBITDA): 10x to 12x EBITDA. The trophy tier for general dentistry. 12x is generally the practical ceiling for general practices outside extraordinary cases.
Specialty practices (any size): 10x to 14x+ EBITDA. Orthodontics, oral surgery, endodontics, periodontics, and pediatric dentistry command structural premiums of 20-40% over general dentistry because of sticky, referral-driven, high-margin revenue.
| Practice Category | Size | 2026 Multiple | Buyer Type |
|---|---|---|---|
| Single-location general | Under $1M EBITDA | 5x–7x EBITDA | DSO add-ons, associate buyers |
| Regional add-on | $1M–$3M EBITDA | 7x–9x EBITDA | Mid-tier DSOs, regional groups |
| Emerging platform | $3M–$5M EBITDA | 9x–11x EBITDA | PE-backed DSOs |
| Platform-grade | $5M+ EBITDA | 10x–12x EBITDA | Large DSO platforms |
| Specialty (any size) | Any | 10x–14x+ EBITDA | DSOs, specialty roll-ups |
The Single Biggest Driver: Scale
The biggest factor in your multiple is whether you have one location or three.
Going from 1 to 3 locations typically doubles your multiple and triples your EBITDA, which is why platform creation is the fastest path to a $5M+ exit.
The same practice can be worth 2x more depending on whether the buyer treats it as a platform or an add-on. A single-location practice at $400K EBITDA at 5x to 7x is worth $2.0M to $2.8M.
A 3-location version of essentially the same operation at $2.4M EBITDA at 7x to 9x is worth $16.8M to $21.6M. The 5x enterprise value gap comes from scale, not from running the practice differently.
How Normalized EBITDA Works (And Why It Matters)
DSOs do not pay on your current profit. They calculate normalized EBITDA, which is what your earnings would be under their operational framework. This number often differs significantly from your books.
What DSOs add back: excess owner compensation (anything above market-rate associate pay, typically 25-30% of doctor production), personal expenses run through the practice, and one-time non-recurring costs.
What DSOs subtract: corporate overhead allocations, technology licensing fees, and a market-rate clinical compensation deduction for the owner-dentist’s production.
This is why the same practice can show $400K SDE (seller’s discretionary earnings, the solo-buyer metric) and $200K adjusted EBITDA (the DSO metric). The owner-dentist’s labor gets valued at market rate and deducted, because the DSO has to pay someone to do that clinical work after you leave.
The DSO Deal Structure: What the Headline Hides
A $5M DSO offer is not $5M in your pocket. The structure determines what you actually realize. Here is the typical 2026 breakdown:
Cash at close: 60-80%. This is the guaranteed, take-home portion paid at closing. On a $5M deal, that is $3M to $4M.
Rollover equity: 15-40%. You reinvest a portion of proceeds into the DSO’s parent entity. Positioned as a “second bite at the apple” when the DSO recapitalizes or sells in 3-7 years. Illiquid until then, and worth what the platform delivers, which could be 2-3x or could be less than you rolled.
Earnout: the remainder. Performance-contingent payments tied to retained EBITDA or production targets over 12-36 months (24 months is most common). Only paid if you hit the targets.
The critical insight: only the cash at close is guaranteed. Earnouts depend on hitting performance targets. Equity rollover is illiquid until the DSO itself is sold. A “premium” DSO offer can net less than a “modest” individual buyer offer once all the adjustments play out.
For a full breakdown of these mechanics, see our guide to dental practice earnouts and equity rollovers.
What You Give Up: The Non-Financial Terms
DSO deals come with commitments that individual buyer deals do not:
Employment commitment. Expect a 3-5 year employment agreement post-sale, practicing as a clinical associate. Your compensation shifts from owner distributions to associate pay (typically 25-30% of collections).
Clinical autonomy clauses. Legally, you retain control over patient care (the corporate practice of dentistry doctrine). But the DSO controls all non-clinical aspects and sets performance expectations.
Non-compete. Standard 2-5 year non-compete within a 10-25 mile radius.
Equity forfeiture risk. Rollover equity can be subject to forfeiture if you’re terminated for cause or breach the agreement. You often have little say over when the DSO exits.
Who’s Buying: The 2026 DSO Landscape
There are 21+ active US dental DSO PE platforms in 2026. Approximately 18-22% of US dental practices are now DSO-affiliated, up from 7% in 2015.
Major general-dentistry platforms: Heartland Dental (KKR), Aspen Dental (Leonard Green + Ares), Pacific Dental Services, MB2 Dental (Charlesbank + Warburg Pincus), Smile Brands (New Mountain Capital), Mortenson Dental Partners (Audax + Genstar), Dental Care Alliance (Quad-C).
Specialty consolidators: Smile Doctors and Specialty Dental Brands (both Linden Capital), USOSM (OMERS), Great Expressions (Roark Capital).
The 2026 driver: 61% of surveyed DSOs reported their PE backers expect a moderate or high increase in acquisition activity in 2026, and 78% anticipate recapitalizations within 12-36 months.
Combined with an aging cohort of boomer owners and declining solo ownership (down from 84.7% in 2005 to 72.5% in 2023), supply and demand are both rising.
How to Read a DSO Offer
Most dentists receive a DSO letter of intent and focus on the headline number. That is the wrong starting point. The right process:
- Separate guaranteed from contingent. Cash at close is real. Earnout and rollover are probabilistic.
- Apply a realistic probability to the earnout based on the targets and the DSO’s operational track record.
- Evaluate the rollover against the DSO’s growth plan, PE backing, and exit timeline.
- Calculate expected realized value, not the maximum possible outcome.
- Compare against alternatives before deciding, including selling to an associate or a smaller regional group.
The LOI is the most important document in your sale, and DSO development teams are trained negotiators who have done hundreds of deals.
Even non-binding terms create strong anchoring effects. Once “agreed,” changing them is treated as bad-faith renegotiation.
DSO Acquisition Offers FAQ
What multiple do DSOs pay for dental practices in 2026?
DSOs pay 5x to 8x EBITDA for single-location general practices, 8x to 11x for multi-location groups with $1M+ EBITDA, and 10x to 14x+ for specialty practices (orthodontics, oral surgery, endodontics). The multiple is based on normalized EBITDA, not collections.
How much of a DSO offer is paid in cash?
Typically 60-80% of the deal value is cash at close. The remaining 15-40% is rollover equity in the DSO’s parent entity, plus earnouts tied to performance over 12-36 months. Only the cash at close is guaranteed.
What is normalized EBITDA in a DSO deal?
Normalized EBITDA is what your practice’s earnings would be under the DSO’s operational framework. DSOs add back excess owner compensation and personal expenses, then subtract a market-rate clinical compensation deduction for your production plus corporate overhead. The same practice can show $400K SDE and $200K adjusted EBITDA.
How long do I have to keep working after selling to a DSO?
Most DSO deals require a 3-5 year employment commitment, practicing as a clinical associate at production-based compensation (typically 25-30% of collections). This is much longer than the 30-90 day transition typical of an individual buyer sale.
Is rollover equity worth it?
Rollover equity (15-40% of deal value) can produce a “second bite at the apple” if the DSO recapitalizes or sells at a higher multiple in 3-7 years. It can be worth 2-3x what you rolled, or less than you invested if the platform underperforms. It is illiquid, often subject to forfeiture, and you usually have little control over the exit timing.
Do specialty practices get higher DSO offers?
Yes. Specialty practices (orthodontics, oral surgery, endodontics, periodontics, pediatric) command 10x to 14x+ EBITDA, a 20-40% premium over general dentistry, because of sticky referral-driven revenue and high margins. Specialty transitions can also run longer (7-10 years vs. 2-5 for general dentistry).
Should I take a DSO offer or sell to an associate?
DSOs typically pay higher headline multiples but require multi-year commitments, compensation reduction to associate rates, and complex earnout/rollover structures. Selling to an associate is simpler and preserves autonomy but usually at 70-80% of fair market value with seller financing. The right choice depends on your retirement timeline, your willingness to keep practicing, and your appetite for second-bite economics.